Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Longitudinal Viral Shedding Analysis in Urine as a Non-Invasive Biomarker for Vector Persistence

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Longitudinal Viral Shedding Analysis in Urine as a Non-Invasive Biomarker for Vector Persistence

Longitudinal Viral Shedding Analysis in Urine for AAV Vector Persistence

CELL & GENE | RNA | BIOLOGICS

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Executive Summary (TL;DR): Longitudinal analysis of viral vector shedding in urine provides a non-invasive, quantitative method to monitor AAV vector clearance and persistence. This approach generates key kinetic data for safety and biodistribution assessments, supporting a more refined understanding of vector behavior over time without reliance on terminal endpoints. The resulting dataset strengthens regulatory submissions by thoroughly characterizing the potential for environmental exposure and informing the overall risk profile of a gene therapy candidate.

Frequently Asked Questions: AAV Shedding in Urine

    What is the primary advantage of using urine for viral shedding analysis?

    A: Urine collection is non-invasive, enabling repeated, longitudinal sampling from the same subject. This refines the kinetic profile of vector clearance, reduces animal usage in alignment with the 3Rs, and provides a more complete dataset compared to single-point terminal collection.

    Which quantification method is used for AAV vector DNA in urine?

    A: Franklin Biolabs employs highly sensitive and specific quantitative PCR (qPCR) and droplet digital PCR (ddPCR) assays. These GxP-compliant methods accurately quantify vector DNA sequences, even at low concentrations, ensuring robust and reliable data for regulatory review.

    How does urine shedding data correlate with vector persistence in target tissues?

    A: While not a direct measure of target tissue transduction, the shedding profile in urine reflects systemic vector clearance. A prolonged shedding curve can indicate slower systemic clearance and a longer-term presence of the vector, which is a key safety parameter for assessing non-target tissue biodistribution and potential for off-target effects.

    What regulatory considerations apply to viral shedding studies?

    A: Global regulatory bodies require comprehensive shedding data to assess the risk of horizontal transmission to untreated individuals and to evaluate potential environmental impact. A well-designed longitudinal study provides the necessary data to build a robust safety narrative for an Investigational New Drug (IND) application.

The Rationale for Non-Invasive Vector Monitoring

Understanding the persistence and clearance kinetics of an AAV vector is fundamental to building a comprehensive safety profile. Traditional biodistribution studies often rely on terminal tissue collection at predefined time points. This approach, while informative, provides only static snapshots and requires large subject cohorts to construct a kinetic curve.

Longitudinal analysis of vector shedding in excreta, particularly urine, offers a more dynamic and refined alternative. By collecting samples from the same subjects over the entire study duration, we can construct a high-resolution clearance profile that accurately models the vector’s systemic behavior. This methodology directly supports key Animal Welfare principles, including Reduction and Refinement, as credited by AAALAC and the USDA.

<a href=”

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Correlating Systemic Clearance with Vector Biology

The shedding profile is intrinsically linked to the fundamental biology of the AAV vector. The choice of capsid and the structure of the vector’s DNA both influence how the vector interacts with host systems and is ultimately cleared.

  • Vector DNA Structure: The molecular fate of the vector’s genetic material post-transduction impacts its long-term persistence. Studies show that the configuration of the vector’s DNA, such as conventional single-stranded versus self-complementary constructs, can influence its stability and processing within the cell (PMID: 20113166). A non-invasive shedding analysis provides a systemic correlate to these molecular events, tracking the clearance of vector DNA that does not result in stable transduction.

  • Vector Serotype and Tropism: The AAV serotype dictates tissue tropism and biodistribution. Research comparing serotypes like rAAV2/5, rAAV2/7, and rAAV2/8 has demonstrated clear differences in transduction efficiency and cellular targets (PMID: 17343566). These tropism profiles directly affect which non-target tissues may serve as vector reservoirs, influencing the magnitude and duration of shedding detected in urine.

Franklin Biolabs’ GxP Bioanalytical Platform

Developing a robust, IND-enabling data package requires precise and validated bioanalytical methods. Within our >100,000 sq ft facility, Franklin Biolabs has established a dedicated GxP bioanalytical laboratory to support these pivotal studies. Our platform utilizes qualified qPCR and ddPCR assays to deliver sensitive, specific, and reproducible quantification of vector DNA from complex biological matrices like urine.

This analytical rigor is integrated into our preclinical programs, which are designed to support an 18-24 month IND timeline. Since 2019, programs developed by our scientific leadership have achieved a 100% IND success rate, a legacy of quality we continue under the Franklin Biolabs brand, which launched in 2024.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

By providing precise, longitudinal shedding data, we equip sponsors with a clear understanding of their vector’s in vivo behavior. This information is vital for making informed decisions on candidate selection and for constructing a compelling safety narrative for regulatory submission.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities